共 727 条
[1]
Trivers KF(2009)The epidemiology of triple-negative breast cancer, including race Cancer Causes Control 20 1071-1082
[2]
Lund MJ(2014)Two decades after BRCA: setting paradigms in personalized cancer care and prevention Science 343 1466-1470
[3]
Porter PL(2014)Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis Clin Genet 85 43-48
[4]
Liff JM(2015)Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer J Clin Oncol 33 304-311
[5]
Flagg EW(2005)Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913-917
[6]
Coates RJ(2005)Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917-921
[7]
Eley JW(2014)Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Ann Oncol 25 1656-1663
[8]
Couch FJ(2011)Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 852-861
[9]
Nathanson KL(2010)Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235-244
[10]
Offit K(2012)Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 1382-1392